Jadoon, Khalid A., Ratcliffe, Stuart H., Barrett, David A., Thomas, E. Louise, Stott, Colin, Bell, Jimmy D., O'Sullivan, Saoirse and Tan, Garry D.
(2016)
Efficacy and safety of Cannabidiol and Tetrahydrocannabivarin on glycemic and lipid parameters in patients with Type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group pilot study.
Diabetes Care, 39
(10).
pp. 1777-1786.
ISSN 1935-5548
Full text not available from this repository.
Abstract
OBJECTIVE Cannabidiol (CBD) and Δ9-tetrahydrocannabivarin (THCV) are nonpsychoactive phytocannabinoids affecting lipid and glucose metabolism in animal models. This study set out to examine the effects of these compounds in patients with type 2 diabetes.
RESEARCH DESIGN AND METHODS In this randomized, double-blind, placebo-controlled study, 62 subjects with noninsulin-treated type 2 diabetes were randomized to five treatment arms: CBD (100 mg twice daily), THCV (5 mg twice daily), 1:1 ratio of CBD and THCV (5 mg/5 mg, twice daily), 20:1 ratio of CBD and THCV (100 mg/5 mg, twice daily), or matched placebo for 13 weeks. The primary end point was a change in HDL-cholesterol concentrations from baseline. Secondary/tertiary end points included changes in glycemic control, lipid profile, insulin sensitivity, body weight, liver triglyceride content, adipose tissue distribution, appetite, markers of inflammation, markers of vascular function, gut hormones, circulating endocannabinoids, and adipokine concentrations. Safety and tolerability end points were also evaluated.
RESULTS Compared with placebo, THCV significantly decreased fasting plasma glucose (estimated treatment difference [ETD] = −1.2 mmol/L; P < 0.05) and improved pancreatic β-cell function (HOMA2 β-cell function [ETD = −44.51 points; P < 0.01]), adiponectin (ETD = −5.9 × 106 pg/mL; P < 0.01), and apolipoprotein A (ETD = −6.02 μmol/L; P < 0.05), although plasma HDL was unaffected. Compared with baseline (but not placebo), CBD decreased resistin (−898 pg/ml; P < 0.05) and increased glucose-dependent insulinotropic peptide (21.9 pg/ml; P < 0.05). None of the combination treatments had a significant impact on end points. CBD and THCV were well tolerated.
CONCLUSIONS THCV could represent a new therapeutic agent in glycemic control in subjects with type 2 diabetes.
| Item Type: |
Article
|
| RIS ID: |
https://nottingham-repository.worktribe.com/output/974684 |
| Additional Information: |
This is an author-created, uncopyedited electronic version of an article accepted for publication
in Diabetes Care. The American Diabetes Care Association (ADA), publisher of Diabetes Care, is not responsible for any errors or omissions in this version of the manuscript
or any version derived from it by third parties. The definitive publisher-authenticated version is available in print and online at http://care.diabetesjournals.org/content/39/10/1777 |
| Schools/Departments: |
University of Nottingham, UK > Faculty of Medicine and Health Sciences > School of Medicine > Division of Medical Sciences and Graduate Entry Medicine
University of Nottingham, UK > Faculty of Science > School of Pharmacy |
| Identification Number: |
https://doi.org/10.2337/dc16-0650 |
| Depositing User: |
Eprints, Support
|
| Date Deposited: |
21 Oct 2016 09:52 |
| Last Modified: |
04 May 2020 20:00 |
| URI: |
https://eprints.nottingham.ac.uk/id/eprint/37816 |
Actions (Archive Staff Only)
 |
Edit View |
Tools
Tools
